 Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimers treatment. The post In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimers Drug appeared first on Investors Business Daily. 